Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial

References

• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–527.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281.
   PubMed Web of Science ®Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–2271.
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–539.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480.
   PubMed Web of Science ®Google Scholar
• Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Rybelsus summary of product characteristics. May 2020 . [cited 2020 Dec 8]. Available from: https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf.
   Google Scholar
• Food and Drug Administration. Rybelsus prescribing information. September 2019. [cited 2020 Dec 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf.
   Google Scholar
• Indu R, Adhikari A, Maisnam I, et al. Polypharmacy and comorbidity status in the treatment of type 2 diabetic patients attending a tertiary care hospital: an observational and questionnaire-based study. Perspect Clin Res. 2018;9(3):139–144.
   PubMedGoogle Scholar
• Jali MV, Kambar S, Jali SM, et al. Prevalence of thyroid dysfunction among type 2 diabetes mellitus patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;11 Suppl 1: S105–S108.
   PubMedGoogle Scholar
• Barmpari ME, Kokkorou M, Micheli A, et al. Thyroid dysfunction among Greek patients with type 1 and type 2 diabetes mellitus as a disregarded comorbidity. J Diabetes Res. 2017;2017:6505814.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Xu F, Shen J, et al. Prevalence of thyroid dysfunction in older Chinese patients with type 2 diabetes – a multicenter cross-sectional observational study across China. PLoS One. 2019;14(5):e0216151.
   PubMed Web of Science ®Google Scholar
• Song F, Bao C, Deng M, et al. The prevalence and determinants of hypothyroidism in hospitalized patients with type 2 diabetes mellitus. Endocrine. 2017;55(1):179–185.
   PubMed Web of Science ®Google Scholar
• Talwalkar P, Deshmukh V, Bhole M. Prevalence of hypothyroidism in patients with type 2 diabetes mellitus and hypertension in India: a cross-sectional observational study. Diabetes Metab Syndr Obes. 2019;12:369–376.
   PubMed Web of Science ®Google Scholar
• IMS Institute for Healthcare Informatics. Medicines use and spending in the U.S. A review of 2015 and outlook to 2020. 2016. [cited 2020 Nov 10]. Available from: https://morningconsult.com/wp-content/uploads/2016/04/IMS-Institute-US-Drug-Spending-2015.pdf.
   Google Scholar
• Colucci P, Yue CS, Ducharme M, et al. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol. 2013;9(1):40–47.
   PubMedGoogle Scholar
• Wartofsky L. Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin Pharmacother. 2002;3(6):727–732.
   PubMedGoogle Scholar
• Virili C, Antonelli A, Santaguida MG, et al. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2019;40(1):118–136.
   PubMed Web of Science ®Google Scholar
• Virili C, Brusca N, Capriello S, et al. Levothyroxine therapy in gastric malabsorptive disorders. Front Endocrinol (Lausanne). 2021;11:621616.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. Levothyroxine summary of product characteristics (Mercury Pharma). February 2016. [cited 2020 Nov 10]. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con676411.pdf.
   Google Scholar
• World Medical Association. Declaration of Helsinki. Recommendations guiding medical doctors in biomedical research involving human subjects. 48th WMA General Assembly; 1996 October 22–26; Somerset West, Western Cape Province, South Africa.
   Google Scholar
• International Conference on Harmonisation. ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1). ICH. June 10, 1996.
   Google Scholar
• Food and Drug Administration. FDA Code of Federal Regulations, 21 Code of Federal Regulations 312.120. Foreign clinical studies not conducted under an IND. FDA; 2014.
   Google Scholar
• Food and Drug Administration. Guidance for industry - drug interaction studies - study design, data analysis, implications for dosing and labeling recommendations. Draft guidance. FDA; February 2012.
   Google Scholar
• European Medicines Agency. Guideline on the investigation of drug interactions. EMA; 2012.
   Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry - levothyroxine sodium tablets - in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. FDA; 2000.
   Google Scholar
• Food and Drug Administration. Draft guidance on levothyroxine sodium. FDA; 2014.
   Google Scholar
• Bækdal TA, Thomsen M, Kupcova V, et al. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314–1323.
   PubMed Web of Science ®Google Scholar
• Baekdal TA, Breitschaft A, Navarria A, et al. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018;14(8):869–877.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation. ICH Harmonised Tripartite Guideline E9. statistical principles for clinical trials, step 4 version. ICH; February 5, 1998.
   Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–1470.
   PubMed Web of Science ®Google Scholar
• Granhall C, Sondergaard FL, Thomsen M, et al. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571–1580.
   PubMed Web of Science ®Google Scholar
• Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother. 2012;46(5):710–717.
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719–2725.
   PubMed Web of Science ®Google Scholar
• Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–619.
   PubMed Web of Science ®Google Scholar
• Dahl K, Brooks A, Almazedi F, et al. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1594–1603.
   Web of Science ®Google Scholar
• Baekdal TA, Borregaard J, Hansen CW, et al. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet. 2019;58(9):1193–1203.
   PubMed Web of Science ®Google Scholar
• Jordy AB, Breitschaft A, Christiansen E, et al. Oral semaglutide does not affect the bioavailability of the combined oral contraceptive ethinylestradiol/levonorgestrel. Diabetes. 2018;67(Supplement 1):1135-P.
   Google Scholar
• Agnihothri RV, Courville AB, Linderman JD, et al. Moderate weight loss is sufficient to affect thyroid hormone homeostasis and inhibit its peripheral conversion. Thyroid. 2014;24(1):19–26.
   PubMed Web of Science ®Google Scholar
• Roef G, Lapauw B, Goemaere S, et al. Body composition and metabolic parameters are associated with variation in thyroid hormone levels among euthyroid young men. Eur J Endocrinol. 2012;167(5):719–726.
   PubMed Web of Science ®Google Scholar